The United Bio-technology (hengqin) Co., Ltd.

This study tests an injection called UBT251 in 180 adults who are overweight or obese and have chronic kidney disease. The goal is to see if it can reduce protein in the urine, a sign of kidney damage, over 24 weeks. Participants will receive either the drug or a placebo, and the…

This study tests an experimental drug called UBT251 for people with MASH, a serious liver condition. The goal is to see if the drug can improve liver health without making scarring worse. About 156 adults with moderate to advanced liver scarring will receive either UBT251 or a pl…